|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Categories: Yahoo FinanceGet free summary analysis Our analysis is based on comparing Teva Pharmaceutical Industries Ltd. with the following peers – Mylan N.V., Sanofi Sponsored ADR, Novartis AG Sponsored ADR, GlaxoSmithKline plc Sponsored ADR, Valeant Pharmaceuticals International Inc, Pfizer Inc., Merck & Co., Inc., Dr. Reddy’s Laboratories Ltd. Sponsored ADR, Takeda Pharmaceutical Co. Ltd. Sponsored ADR and ... Read more (Read more...)
Alnylam (ALNY) and partner Sanofi RNAi therapeutic patisiran met its primary efficacy endpoint and all secondary endpoints in the phase III APOLLO study.
GlaxoSmithKline plc (GSK) along with partner Innoviva reports positive results from a phase III study, evaluating a single inhaler triple therapy in patients with COPD.